Edwards Larry G.

Chief Executive Officer, DirectorLA JOLLA PHARMACEUTICAL CO (LJPC) · full profile →Form 4 · filed Aug 24, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
28
1 non-derivative · 27 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 22, 2022Disposed to issuer(D)12K$6.23$75K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 22, 2022Disposed to issuer(D)3340
Aug 22, 2022Disposed to issuer(D)3610
Aug 22, 2022Disposed to issuer(D)400K0
Aug 22, 2022Disposed to issuer(D)278K0
Aug 22, 2022Disposed to issuer(D)3220
Aug 22, 2022Disposed to issuer(D)3040
Aug 22, 2022Disposed to issuer(D)3580
Aug 22, 2022Disposed to issuer(D)3140
Aug 22, 2022Disposed to issuer(D)2750
Aug 22, 2022Disposed to issuer(D)3150
Aug 22, 2022Disposed to issuer(D)3580
Aug 22, 2022Disposed to issuer(D)3740
Aug 22, 2022Disposed to issuer(D)3380
Aug 22, 2022Disposed to issuer(D)3200
Aug 22, 2022Disposed to issuer(D)6760
Aug 22, 2022Disposed to issuer(D)3410
Aug 22, 2022Disposed to issuer(D)3350
Aug 22, 2022Disposed to issuer(D)3360
Aug 22, 2022Disposed to issuer(D)3460
Aug 22, 2022Disposed to issuer(D)3200
Aug 22, 2022Disposed to issuer(D)2330
Aug 22, 2022Disposed to issuer(D)419K0
Aug 22, 2022Disposed to issuer(D)2730
Aug 22, 2022Disposed to issuer(D)2960
Aug 22, 2022Disposed to issuer(D)4K0
Aug 22, 2022Disposed to issuer(D)3200
Aug 22, 2022Disposed to issuer(D)3500

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-22-029657) within minutes of acceptance. Every field above traces to the original document. Verify it directly: